Joseph et al. showed that CD133 was significantly associated with poor prognostic characteristics in breast cancer patients, such as high histological grade, younger age, high Nottingham Prognostic Index, and estrogen and progesterone receptor negative subtypes that often are chemoresistant [177]. The gene discussed is PROM1; the disease is breast carcinoma.